Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2022-03-18 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-03-18 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated March 16, 2022, for Aeglea Biotherapeutics, Inc. The content focuses on the departure of a director/officer (Steven Weber) and the appointment of a new principal accounting officer (Jonathan Alspaugh). There is no financial data or report attached; the document is an announcement of management changes. This fits the category of Board/Management Information (MANG). The document length is 4103 characters, which is relatively short and consistent with a management change announcement rather than a full report.
2022-03-18 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-15 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-15 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes details about the registration of additional shares under these plans and incorporates by reference other filings like the Annual Report on Form 10-K. The document is not a financial report itself but a regulatory filing related to securities registration. It does not contain financial statements or earnings data but is a formal registration statement under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS).
2022-03-08 English
10-K
Annual Report FY 2021
2022-03-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.